If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. |
|
|
Thread Tools | Display Modes |
#1
|
|||
|
|||
[VaxActivists] Shedding of FLUMIST - all flumist - regular and AH1N1
May want to go to your schools - superintendents, principals, school boards,
teachers, with this information................... This should not be given in schools (or stores or anywhere) THE CDC's Pink Book says in Chapter 10 on Page 142 (if you click on the Chapter 10 link, it is on page 8 of your PDF but still page 142) http://www.cdc.gov/vaccines/pubs/pin...nloads/flu.pdf Publications: The Pink Book: Chapters Epidemiology and Prevention of Vaccine Preventable Diseases Updated 11th Edition, (May 2009) Vaccinated children can shed vaccine viruses in nasopharyngeal secretions for up to 3 weeks. One instance of transmission of vaccine virus to a contact has been documented. The transmitted virus retained its attenuated, cold-adapted, temperature-sensitive characteristics. The frequency of shedding of vaccine strains by persons 549 years of age has not been determined. ********* http://www.imakenews.com/idf/e_artic....cfm?x=b11,0,w Q: What are the potential complications of the FluMistT vaccine? A: The most common adverse events associated with the vaccine in normal individuals were nasal congestion, runny nose, sore throat and a cough. Although there is no specific information available, it is anticipated that if a person with a primary immune deficiency receives FluMistT (s)he would be more likely to develop complications. If a close contact is vaccinated, the resulting viral shedding could cause a person with a primary immune deficiency disease to become infected with the flu vaccine strains. (See A7 below) Q: What is the risk to individuals with primary immune deficiency disorders if a close contact is vaccinated with FluMistT? A: During a clinical trial with FluMistT in a day care center, there was documented transmission from vaccinated children to unvaccinated children. Viral shedding following the administration of FluMistT typically continues for about a week on the average, but may be as long as three weeks. The risk of transmission in the day care center setting was estimated at 2.4% or one in approximately 42 children. The risk could be higher if different children in the center receive the vaccine at different times over the fall. Healthcare workers who receive FluMistT may also present a possible way for a person with a primary immune deficiency disease to become infected with the flu vaccine strains. Although there is no data about transmission of the live vaccine virus from vacinees to immune compromised contacts and subsequent development of disease, the Centers for Disease Control and Prevention have stated that the inactivated vaccine (flu shot) is preferred over live, intranasal influenza vaccine (FluMistT) for physicians, nurses, family members, or anyone else coming in close contact with anyone with a weakened immune system. School authorities may want to advise their immune deficient pupils if FluMistT is being administered in the school system. This information may be especially useful to those with T cell or combined T and B cell immune deficiencies. http://www.imakenews.com/idf/e_artic....cfm?x=b11,0,w Q: How can you reduce your risk of complications from the FluMistT vaccine? A: To reduce the risk of contracting the flu vaccine strains, the Immune Deficiency Foundation's Medical Advisory Committee has made the following recommendations: a.. Because it is a live virus vaccine, people with primary immune deficiency diseases should NOT receive the FluMistT vaccine. b.. The FluMistT vaccine is not recommended for close contacts of primary immune deficient patients. c.. Primary immune deficient patients should talk to their doctors to see if it may be advisable to receive preventive medicine to avoid becoming infected with the FluMistT strains of the flu. d.. Primary immune deficient patients exposed through close contact to FluMistT, should see their doctor immediately, as (s)he may advise a treatment medicine. e.. School authorities may want to advise their immune deficient pupils if FluMistT is being administered in the school system. This information may be especially useful to those with T cell or combined T and B cell immune deficiencies. f.. Family members and healthcare workers in close contact with immune deficient patients should be advised to receive the killed virus flu shot, rather than the FluMistT vaccine. The package insert - they left out the statement that was in the first insert when it first came out.................now they have all these words to say possibly shedding up to 21 days but at the end say they don't know. The original package insert said" In the section of the FlumMist package insert labeled "PRECAUTIONS," the manufacturer states the following warning: "FluMist® recipients should avoid close contact with immunocompromised individuals for at least 21 days." The warning is specifically directed toward those living in the same household with an immunocompromised person, but the on-going release of live viruses throughout the community may be a significant risk to everyone who has a weak, or weakened, immune system. and more from Risks of FluMist Vaccine by Dr. Sherri Tenpenny http://www.vaccineinfo.net/immunizat...ne_risks.shtml The number of immunocompromised people in the United States is enormous: a.. It is estimated that at least 10%, or more than 28 million people have eczema. [ 11] b.. More than 8.5 million people have cancer. [ 12] c.. There are reported to be 850,000 individuals with diagnosed and undiagnosed HIV infection or AIDS [ 13] and d.. Based on 2001 data, there were 184,000 organ recipients [ 14] An even more extensive list of at-risk people includes the untold millions on drugs called corticosteroids. Prednisone®, Medrol®, and a variety of similar medications are given to both adults and children. These drugs are prescribed for dozens of conditions including asthma; allergies; eczema; emphysema; Crohn's disease; multiple sclerosis; herniated spinal discs; acute muscular pain syndromes; and all types of rheumatoid and autoimmune diseases. As much as 60% of the entire population could be considered to be "chemically immunosuppressed." It is important to realize that FluMist is CONTRAINDICATED for people who are immunocompromised. People who receive FluMist and are living with an immunocompromised person put their loved ones at risk. http://gateway.nlm.nih.gov/MeetingAb...102270663.html shedding info below from 2001 A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Transmissibility and Phenotypic Stability of a Live, Attenuated, Cold-Adapted Influenza Virus Vaccine (CAIV-T) in Children Attending Day Care. VESIKARI T, KARVONEN A, KORHONEN T, EDELMAN K, VAINIONPAA R, SALMI A, FAST P, TAMIGNIAUX A, SAVILLE M, RAPPAPORT R, ZAMB T, FORREST B; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.). Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. G-450. Univ. Tampere, Tampere, Finland BACKGROUND: CAIV-T has been shown to be efficacious and effective in healthy children and adults. This study was designed to estimate the frequency at which CAIV-T vaccine viruses may be transmitted between children in day care. METHODS: 197 children aged /=8 to 36 mos. attending day care were randomized to receive a single intranasal dose of either 10[7] TCID[50] of each CAIV-T strain (n = 98) or placebo (n = 99). Viral shedding was determined for 21 days by culture of nasal swabs. Vaccine virus was identified by type and subtype, and analyzed for cold-adapted (ca) temperature-sensitive (ts) phenotype. Subjects were monitored for reactogenicity events (predefined events within 21 days of dosing). Serious adverse events were collected for a 42-day period. RESULTS: 80% of CAIV-T recipients shed /=1 vaccine strain (32% A/H1N1; 12% A/H3N2; 74% influenza B); 6% shed two A strains; and 6% shed all 3 strains. Mean shedding duration was 7.6 days (A/H1N1: 5.3; A/H3N2: 8.5; B: 7.0). One placebo recipient shed influenza B vaccine virus, confirmed by phenotype and genotype analysis, indicating transmission. Estimated transmission rate was 1.75% for the evaluable analysis population (90% CI upper bound: 8.05%). The ca ts phenotype of all shed vaccine viruses was preserved. There were no statistically significant differences in reactogenicity episodes between study groups. CONCLUSION: CAIV-T was well tolerated in young children aged /=8 to 36 mos. CAIV-T may be transmitted between young children in close contact, with an estimated rate of 1.75% (90% CI: 8.05%). All shed and transmitted virus retained the ca ts phenotype. http://www.fda.gov/downloads/Biologi.../UCM182406.pdf 14.5 Transmission Study FluMist contains live attenuated influenza viruses that must infect and replicate in cells lining the nasopharynx of the recipient to induce immunity. Vaccine viruses capable of infection and replication can be cultured from nasal secretions obtained from vaccine recipients. The relationship of viral replication in a vaccine recipient and transmission of vaccine viruses to other individuals has not been established. Using the frozen formulation, a prospective, randomized, double-blind, placebo-controlled trial was performed in a daycare setting in children 3 years of age to assess the transmission of vaccine viruses from a vaccinated individual to a non-vaccinated individual. A total of 197 children 8-36 months of age were randomized to receive one dose of FluMist (n=98) or placebo (n=99). Virus shedding was evaluated for 21 days by culture of nasal swab specimens. Wild-type A (H3N2) influenza virus was documented to have circulated in the community and in the study population during the trial, whereas Type A (H1N1) and Type B strains did not. At least one vaccine strain was isolated from 80% of FluMist recipients; strains were recovered from 1-21 days post vaccination (mean duration of 7.6 days ± 3.4 days). The cold-adapted (ca) and temperature-sensitive (ts) phenotypes were preserved in 135 tested of 250 strains isolated at the local laboratory. Ten influenza isolates (9 influenza A, 1 influenza B) were cultured from a total of seven placebo subjects. One placebo subject had mild symptomatic Type B virus infection confirmed as a transmitted vaccine virus by a FluMist recipient in the same playgroup. This Type B isolate retained the ca, ts, and att phenotypes of the vaccine strain, and had the same genetic sequence when compared to a Type B virus cultured from a vaccine recipient within the same playgroup. Four of the influenza Type A isolates were confirmed as wild-type A/Panama (H3N2). The remaining isolates could not be further characterized. Assuming a single transmission event (isolation of the Type B vaccine strain), the probability of a young child acquiring vaccine virus following close contact with a single FluMist vaccinee in this daycare setting was 0.58% (95% CI: 0, 1.7) based on the Reed-Frost model. With documented transmission of one Type B in one placebo subject and possible transmission of Type A viruses in four placebo subjects, the probability of acquiring a transmitted vaccine virus was estimated to be 2.4% (95% CI: 0.13, 4.6), using the Reed-Frost model. The duration of FluMist vaccine virus replication and shedding have not been established. and in section 5.4 Altered Immunocompetence Administration of Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal, or FluMist live virus vaccine, to immunocompromised persons should be based on careful consideration of potential benefits and risks. Although FluMist was studied in 57 asymptomatic or mildly symptomatic adults with HIV infection [see Clinical Studies (14.3)], data supporting the safety and effectiveness of FluMist administration in immunocompromised individuals are limited. ONLY TO BE GIVEN to immunocompromised with careful consideration and shedding to all is exposing all. |
Thread Tools | |
Display Modes | |
|
|
Similar Threads | ||||
Thread | Thread Starter | Forum | Replies | Last Post |
FluMist was HYPING VACCINES: AN INVESTIGATION | Todd Gastaldo | Kids Health | 0 | October 19th 04 06:02 AM |
FluMist or FluZone nasal vaccine for children? | sams | Kids Health | 4 | December 12th 03 05:30 AM |
'1918' (also: FluMist: Attn Safeway/Albertson Shoppers) | Todd Gastaldo | Pregnancy | 0 | October 30th 03 11:22 PM |
Truly dangerous and hyped up FluMist | Maryilee | Kids Health | 6 | October 20th 03 12:22 PM |
[OT] When Does the Shedding Slow Down? | Belphoebe | Breastfeeding | 10 | July 21st 03 02:21 PM |